Vivo Capital is a healthcare focused investment firm formed in 1996 with over $1.7 billion under management. Vivo Capital is currently making investments from its $750M eighth fund into promising private and public healthcare companies in the U.S. and greater China.

Vivo employs a unique multi-pronged strategy of identifying and working with companies with promising development stage and commercial stage therapeutic products in the U.S. and revenue stage companies in China. Vivo Capital has offices in Palo Alto, California, Shanghai, Chengdu, and Beijing, China.

With over 100 years of scientific expertise and operating experience in healthcare, Vivo makes investment decisions for the Funds and helps its portfolio companies develop corporate strategy, facilitate strategic alliances including cross-border partnerships, recruit management, and acquire new products and technologies to accelerate growth. Vivo’s current portfolio includes more than 80 private and public biotechnology companies in the areas of biopharmaceuticals, specialty pharmaceuticals, and medical devices.
Nabriva Therapeutics Prices Initial Public Offering
Vienna, Austria and King of Prussia, PA -
September 17, 2015
REGENXBIO Announces Pricing of Initial Public Offering
Rockville, MD - September 16, 2015
Trevena, Inc. Announces Closing of Public Offering of Common Stock
King of Prussia, PA – September 16, 2015